The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice
Cytopathology · 2024
DOI: 10.1111/cyt.13246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytopathology, 2024. Verfasst von Paul Hofman und 1 weiteren Autor:innen. Beteiligte Einrichtung: FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, Nice, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The assessment of minimal residual disease (MRD) from blood samples of patients with resected non‐small cell lung carcinoma (NSCLC) is promising and opens up many opportunities for the optimisation of patient care in daily practice. Notably, this includes the potential for escalation or de‐escalation of adjuvant therapies. Thus, the evaluation of MRD status can directly contribute to an increase in the overall survival of early stage NSCLC patients and/or limit therapeutic but also “financial” toxicity. Therefore, several clinical trials recently evaluated MRD in early stage NSCLC by integrating and retrospectively comparing the results of MRD assessments. In this context, there is an urgent need to close the gap between clinical research and the use of the evaluation of MRD in routine daily practice. Further action needs to be taken, particularly in evaluating the pertinence of the detection of MRD in prospective interventional clinical studies. This may be done in part by comparing different parameters, such as the techniques used, the different time points and the cutoffs of MRD assessments. This article investigates the assessment of MRD in non‐small cell lung cancers, with a special focus on the issues associated with the various assays and the limitations of using circulating free DNA analyses for MRD assessment in early stage lung cancer. Recommendations and tips for the optimisation of MRD evaluation in non‐small cell lung cancers are provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, Nice, France.
- Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, Nantes Université, CHU Nantes, Nantes, France.
ORCID-Profile: Paul Hofman
Zitieren
APA
Hofman, P., & Denis, M. G. (2024). The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice. Cytopathology. https://doi.org/10.1111/cyt.13246
Vancouver
Hofman P, Denis MG. The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice. Cytopathology. 2024. doi:10.1111/cyt.13246
BibTeX
@article{Hofman2024,
author = {Hofman, Paul and Denis, Marc G},
title = {The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice},
journal = {Cytopathology},
year = {2024},
doi = {10.1111/cyt.13246}
}
EUVIMED